M&A Deal Summary |
|
|---|---|
| Date | 2025-06-27 |
| Target | Turnstone Biologics |
| Sector | Life Science |
| Buyer(s) | XOMA Royalty |
| Sellers(s) | Eight Roads |
| Deal Type | Add-on Acquisition |
| Advisor(s) | Leerink Partners (Financial) Cooley (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Sector | Life Science |
| Employees | 13 |
| Revenue | 10M USD (2024) |
XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty is based in Emeryville, California.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 5 |
| Sector: Life Science M&A | 2 of 5 |
| Type: Add-on Acquisition M&A Deals | 2 of 5 |
| State: Ontario M&A | 1 of 1 |
| Country: Canada M&A | 1 of 1 |
| Year: 2025 M&A | 1 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-12-02 |
Pulmokine
Rensselaer, New York, United States Pulmokine specializes in developing treatments for pulmonary arterial hypertension (PAH) and other pulmonary diseases. Pulmokine is based in Rensselaer, New York. |
Buy | $20M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-08-04 |
Lava Therapeutics
Utrecht, Netherlands Lava Therapeutics focused on applying its expertise in gamma-delta T cell engagers (TCEs) to transform cancer therapy. The company's platform generates therapeutics that specifically activate a unique and relatively abundant effector gamma-delta T cell subset called Vγ9Vδ2 (Vgamma9-Vdelta2) T cells that have the ability to trigger the activity of immune cells of both the innate and adaptive immune system. Its gamma-delta bsTCEs have demonstrated superior efficacy and safety profiles compared to other bsTCE approaches in preclinical studies and show preferential activity against tumor cells thereby potentially limiting toxicity in healthy tissue. Lava Therapeutics was founded in 2016 and is based in Utrecht, Netherlands. |
Buy | - |
| Category | Private Equity Firm |
|---|---|
| Founded | 1969 |
| PE ASSETS | 11.0B USD |
| Size | Mega |
| Type | Sector Focused |
Eight Roads is a private investment firm focused on a variety of investment opportunities across the US, Europe, and Asia. The Firm is divided into several investment strategies including venture, principal investing, and real estate. Within the principal investments group, Eight Roads backs established growth businesses with long-term capital. Eight Roads does not have any sector preferences, but has experience in fintech, business services, and healthcare. Eight Roads is based in London.
| DEAL STATS | # |
|---|---|
| Overall | 122 of 124 |
| Sector: Life Science M&A | 51 of 51 |
| Type: Add-on Acquisition M&A Deals | 58 of 59 |
| State: Ontario M&A | 1 of 1 |
| Country: Canada M&A | 1 of 1 |
| Year: 2025 M&A | 7 of 9 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-06-19 |
7bridges
London, United Kingdom 7bridges provides an AI powered supply chain management solution with the mission of making it easy for customers to overcome the challenge of data to connect supply to demand and implement world-class logistics. 7bridges was founded in 2016 and is based in London, United Kingdom. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-06-30 |
MoEngage
San Francisco, California, United States MoEngage is an intelligent customer analytics and cross-channel engagement platform that enables hyper-personalization at scale across multiple channels like mobile push, email, in-app, web push, On-site messages, and SMS. MoEngage was founded in 2014 and is based in San Francisco, California. |
Sell | - |
